Literature DB >> 32071060

Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.

C A Colque1,2, A G Albarracín Orio1,2,3, S Feliziani1,2, R L Marvig4, A R Tobares1,2, H K Johansen5,6, S Molin7, A M Smania8,2.   

Abstract

Pseudomonas aeruginosa exploits intrinsic and acquired resistance mechanisms to resist almost every antibiotic used in chemotherapy. Antimicrobial resistance in P. aeruginosa isolates recovered from cystic fibrosis (CF) patients is further enhanced by the occurrence of hypermutator strains, a hallmark of chronic infections in CF patients. However, the within-patient genetic diversity of P. aeruginosa populations related to antibiotic resistance remains unexplored. Here, we show the evolution of the mutational resistome profile of a P. aeruginosa hypermutator lineage by performing longitudinal and transversal analyses of isolates collected from a CF patient throughout 20 years of chronic infection. Our results show the accumulation of thousands of mutations, with an overall evolutionary history characterized by purifying selection. However, mutations in antibiotic resistance genes appear to have been positively selected, driven by antibiotic treatment. Antibiotic resistance increased as infection progressed toward the establishment of a population constituted by genotypically diversified coexisting sublineages, all of which converged to multidrug resistance. These sublineages emerged by parallel evolution through distinct evolutionary pathways, which affected genes of the same functional categories. Interestingly, ampC and ftsI, encoding the β-lactamase and penicillin-binding protein 3, respectively, were found to be among the most frequently mutated genes. In fact, both genes were targeted by multiple independent mutational events, which led to a wide diversity of coexisting alleles underlying β-lactam resistance. Our findings indicate that hypermutators, apart from boosting antibiotic resistance evolution by simultaneously targeting several genes, favor the emergence of adaptive innovative alleles by clustering beneficial/compensatory mutations in the same gene, hence expanding P. aeruginosa strategies for persistence.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosazzm321990; ampCzzm321990; cystic fibrosis; ftsIzzm321990; hypermutability; multidrug resistance

Mesh:

Substances:

Year:  2020        PMID: 32071060      PMCID: PMC7179616          DOI: 10.1128/AAC.02142-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  111 in total

Review 1.  Antibacterial drug discovery in the resistance era.

Authors:  Eric D Brown; Gerard D Wright
Journal:  Nature       Date:  2016-01-21       Impact factor: 49.962

2.  Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.

Authors:  María D Maciá; David Blanquer; Bernat Togores; Jaume Sauleda; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 3.  Parallel evolution and local differentiation in quinolone resistance in Pseudomonas aeruginosa.

Authors:  Alex Wong; Rees Kassen
Journal:  Microbiology       Date:  2011-02-03       Impact factor: 2.777

4.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

Authors:  A Oliver; R Cantón; P Campo; F Baquero; J Blázquez
Journal:  Science       Date:  2000-05-19       Impact factor: 47.728

5.  The Sequence Alignment/Map format and SAMtools.

Authors:  Heng Li; Bob Handsaker; Alec Wysoker; Tim Fennell; Jue Ruan; Nils Homer; Gabor Marth; Goncalo Abecasis; Richard Durbin
Journal:  Bioinformatics       Date:  2009-06-08       Impact factor: 6.937

6.  Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa.

Authors:  N Masuda; N Gotoh; C Ishii; E Sakagawa; S Ohya; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

7.  Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.

Authors:  Shawn T Clark; Utkarshna Sinha; Yu Zhang; Pauline W Wang; Sylva L Donaldson; Bryan Coburn; Valerie J Waters; Yvonne C W Yau; D Elizabeth Tullis; David S Guttman; David M Hwang
Journal:  Int J Antimicrob Agents       Date:  2019-01-19       Impact factor: 5.283

8.  Better prediction of functional effects for sequence variants.

Authors:  Maximilian Hecht; Yana Bromberg; Burkhard Rost
Journal:  BMC Genomics       Date:  2015-06-18       Impact factor: 3.969

Review 9.  Epistasis and the Evolution of Antimicrobial Resistance.

Authors:  Alex Wong
Journal:  Front Microbiol       Date:  2017-02-17       Impact factor: 5.640

10.  Predicting mutational routes to new adaptive phenotypes.

Authors:  Peter A Lind; Eric Libby; Jenny Herzog; Paul B Rainey
Journal:  Elife       Date:  2019-01-08       Impact factor: 8.140

View more
  14 in total

1.  Adaptation and genomic erosion in fragmented Pseudomonas aeruginosa populations in the sinuses of people with cystic fibrosis.

Authors:  Catherine R Armbruster; Christopher W Marshall; Arkadiy I Garber; Jeffrey A Melvin; Anna C Zemke; John Moore; Paula F Zamora; Kelvin Li; Ian L Fritz; Christopher D Manko; Madison L Weaver; Jordan R Gaston; Alison Morris; Barbara Methé; William H DePas; Stella E Lee; Vaughn S Cooper; Jennifer M Bomberger
Journal:  Cell Rep       Date:  2021-10-19       Impact factor: 9.423

2.  Express Yourself: Quantitative Real-Time PCR Assays for Rapid Chromosomal Antimicrobial Resistance Detection in Pseudomonas aeruginosa.

Authors:  Derek S Sarovich; Erin P Price; Danielle E Madden; Olusola Olagoke; Timothy Baird; Jane Neill; Kay A Ramsay; Tamieka A Fraser; Scott C Bell
Journal:  Antimicrob Agents Chemother       Date:  2022-04-25       Impact factor: 5.938

3.  New Sequence Type ST3449 in Multidrug-Resistant Pseudomonas aeruginosa Isolates from a Cystic Fibrosis Patient.

Authors:  Catalina Díaz-Ríos; Marta Hernández; David Abad; Laura Álvarez-Montes; Athanasia Varsaki; David Iturbe; Jorge Calvo; Alain A Ocampo-Sosa
Journal:  Antibiotics (Basel)       Date:  2021-04-23

4.  Within-Host Microevolution of Pseudomonas aeruginosa Urinary Isolates: A Seven-Patient Longitudinal Genomic and Phenotypic Study.

Authors:  Agnès Cottalorda; Marie Leoz; Sandrine Dahyot; François Gravey; Maxime Grand; Thomas Froidure; Fabien Aujoulat; Simon Le Hello; Estelle Jumas-Bilak; Martine Pestel-Caron
Journal:  Front Microbiol       Date:  2021-01-14       Impact factor: 5.640

Review 5.  The methylation-independent mismatch repair machinery in Pseudomonas aeruginosa.

Authors:  Yue Yuan On; Martin Welch
Journal:  Microbiology (Reading)       Date:  2021-12       Impact factor: 2.777

6.  Genome evolution drives transcriptomic and phenotypic adaptation in Pseudomonas aeruginosa during 20 years of infection.

Authors:  Samuel J T Wardell; Jeff Gauthier; Lois W Martin; Marianne Potvin; Ben Brockway; Roger C Levesque; Iain L Lamont
Journal:  Microb Genom       Date:  2021-11

7.  Gene Loss and Acquisition in Lineages of Pseudomonas aeruginosa Evolving in Cystic Fibrosis Patient Airways.

Authors:  Migle Gabrielaite; Helle K Johansen; Søren Molin; Finn C Nielsen; Rasmus L Marvig
Journal:  mBio       Date:  2020-10-27       Impact factor: 7.867

Review 8.  Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors.

Authors:  Irene Jurado-Martín; Maite Sainz-Mejías; Siobhán McClean
Journal:  Int J Mol Sci       Date:  2021-03-18       Impact factor: 5.923

Review 9.  β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects.

Authors:  Karl A Glen; Iain L Lamont
Journal:  Pathogens       Date:  2021-12-18

Review 10.  An Organ System-Based Synopsis of Pseudomonas aeruginosa Virulence.

Authors:  Charles D Morin; Eric Déziel; Jeff Gauthier; Roger C Levesque; Gee W Lau
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.